EconBiz - Find Economic Literature
    • Logout
    • Change account settings
  • A-Z
  • Beta
  • About EconBiz
  • News
  • Thesaurus (STW)
  • Academic Skills
  • Help
  •  My account 
    • Logout
    • Change account settings
  • Login
EconBiz - Find Economic Literature
Publications Events
Search options
Advanced Search history
My EconBiz
Favorites Loans Reservations Fines
    You are here:
  • Home
  • Search: subject_exact:"Pharmaceutical"
Narrow search

Narrow search

Year of publication
Subject
All
Arzneimittel 9,324 Pharmaceuticals 9,194 Pharmaceutical industry 2,876 Pharmaindustrie 2,876 Arzneimittelmarkt 1,482 Pharmaceutical market 1,427 USA 1,116 Impfung 1,105 Vaccination 1,104 United States 1,094 Gesundheitskosten 977 Health care costs 976 Theorie 930 Theory 930 Coronavirus 871 Gesundheitspolitik 862 Drogenkonsum 859 Drug consumption 858 Health care 851 Gesundheitsversorgung 844 Health policy 842 Gesundheitswesen 762 Welt 757 World 757 Health care system 737 Innovation 724 Pharmakologie 682 Pharmacology 679 Patent 621 Drug 573 Droge 566 Impact assessment 525 Wirkungsanalyse 525 Price 509 Preis 508 Deutschland 481 Consumer behaviour 457 Konsumentenverhalten 457 Germany 454 Generic drugs 442
more ... less ...
Online availability
All
Free 4,252 Undetermined 2,034 CC license 222
Type of publication
All
Book / Working Paper 5,397 Article 4,039 Journal 43 Other 1
Type of publication (narrower categories)
All
Article in journal 3,362 Aufsatz in Zeitschrift 3,362 Graue Literatur 1,660 Non-commercial literature 1,660 Working Paper 1,462 Arbeitspapier 1,452 Aufsatz im Buch 466 Book section 466 Hochschulschrift 179 Thesis 128 Collection of articles of several authors 109 Sammelwerk 109 Konferenzschrift 63 Amtsdruckschrift 54 Government document 54 Aufsatzsammlung 50 Case study 38 Fallstudie 38 Conference paper 32 Konferenzbeitrag 32 Conference proceedings 27 Bibliografie enthalten 20 Bibliography included 20 Collection of articles written by one author 19 Sammlung 19 Statistik 17 Amtliche Publikation 14 Lehrbuch 14 Statistics 13 Dissertation u.a. Prüfungsschriften 12 Textbook 12 Bibliografie 11 Market information 9 Marktinformation 9 Rezension 9 Article 8 Mehrbändiges Werk 8 Multi-volume publication 8 non-article 7 research-article 7
more ... less ...
Language
All
English 8,745 German 522 Undetermined 83 French 77 Spanish 23 Italian 20 Swedish 8 Portuguese 4 Danish 3 Dutch 3 Polish 2 Hungarian 1 Russian 1
more ... less ...
Author
All
Lichtenberg, Frank R. 139 Berndt, Ernst R. 103 Kremer, Michael 70 Brekke, Kurt R. 51 Snyder, Christopher M. 46 Philipson, Tomas J. 44 Simon, Kosali Ilayperuma 38 Straume, Odd Rune 38 Danzon, Patricia Munch 37 Lo, Andrew W. 36 Finkelstein, Amy 35 Bate, Roger 33 Frank, Richard G. 32 Jin, Ginger Zhe 32 Vernon, John A. 31 Conti, Rena M. 30 Williams, Heidi 30 McFadden, Daniel 29 Powell, David 29 Dubois, Pierre 28 Granlund, David 28 Heiss, Florian 27 Winter, Joachim 27 Correa, Carlos María 25 Duggan, Mark G. 25 Einav, Liran 25 Kyle, Margaret K. 25 Goldman, Dana P. 24 Kaestner, Robert 24 Chatterjee, Chirantan 23 Wille, Eberhard 23 Birg, Laura 22 Ullrich, Hannes 22 Dalen, Dag Morten 21 Higgins, Matthew J. 21 Lakdawalla, Darius 21 Sood, Neeraj 21 Pauly, Mark V. 20 Sampat, Bhaven N. 20 Cockburn, Iain 19
more ... less ...
Institution
All
National Bureau of Economic Research 357 European Monitoring Centre for Drugs and Drug Addiction 151 OECD 41 European Centre for Disease Prevention and Control 34 European Commission / Directorate-General for Health and Food Safety 26 World Bank 22 World Trade Organization 11 European Medicines Agency 10 European Commission / DG III - Industry 9 European Commission / Directorate-General for Research and Innovation 9 European Parliament / Directorate-General for Internal Policies of the Union 9 Europäische Kommission / Beobachtungsstelle für Drogen und Drogensucht 8 Springer Fachmedien Wiesbaden 8 Europäische Kommission 7 American Enterprise Institute for Public Policy Research 6 Ekonomiska forskningsinstitutet <Stockholm> 5 Food and Drug Administration 5 IGI Global 5 United States / Congress / House / Committee on Government Operations 5 DAK-Gesundheit 4 European Commission / Directorate-General for Migration and Home Affairs 4 Großbritannien / Ministry of Health 4 IMI 2 Joint Undertaking 4 USA / Committee on Ways and Means / Subcommittee on Health 4 eSocialSciences 4 Australia / Parliament / Senate / Standing Committee on Social Welfare 3 CESifo 3 Edward Elgar Publishing 3 Europarat 3 European Commission / Directorate-General for Communication 3 Milieu Ltd. 3 Organisation for Economic Co-operation and Development 3 Peter Lang GmbH 3 South Centre 3 Technopolis Group 3 UNCTAD 3 USA / Congress / Senate / Special Committee on Aging 3 United States / Congress / Senate / Committee on Labor and Public Welfare / Subcommittee on Alcoholism and Narcotics 3 Wissenschaftliches Institut der Ortskrankenkassen 3 medhochzwei Verlag GmbH 3
more ... less ...
Published in...
All
NBER working paper series 358 NBER Working Paper 285 Working paper / National Bureau of Economic Research, Inc. 264 Health economics 133 Journal of health economics 130 The European journal of health economics : HEPAC ; health economics in prevention and care 116 International journal of pharmaceutical and healthcare marketing : IJPHM 87 Discussion paper series / IZA 69 Health affairs : at the intersection of health, health care, and policy 62 CESifo working papers 58 Health marketing quarterly 56 Health economics review 52 Research paper 51 Journal of medical marketing : device, diagnostic and pharmaceutical marketing 49 Discussion papers / CEPR 41 The European journal of health economics 41 Management science : journal of the Institute for Operations Research and the Management Sciences 38 Working paper 38 Journal of illicit economies and development : JIED 36 IZA Discussion Paper 32 European journal of operational research : EJOR 31 International journal of pharmaceutical and healthcare marketing 30 Journal of pharmaceutical finance, economics & policy 30 Applied economics 29 International journal of health economics and management 29 Research policy : policy, management and economic studies of science, technology and innovation 27 International journal of the economics of business 26 Applied economics letters 24 Manufacturing & service operations management : M & SOM 24 The American economic review 24 Economics letters 23 Health care management science 23 International journal of industrial organization 23 Journal of research in pharmaceutical economics 23 CESifo Working Paper Series 22 Forum for health economics & policy : an evolving collection of symposia on important health care issues 21 Research papers / South Centre 21 American economic journal : a journal of the American Economic Association 20 CESifo Working Paper 20 Journal of economic behavior & organization : JEBO 20
more ... less ...
Source
All
ECONIS (ZBW) 9,317 RePEc 58 USB Cologne (EcoSocSci) 55 Other ZBW resources 22 EconStor 20 BASE 6 ArchiDok 2
more ... less ...
Showing 1 - 50 of 9,480
Cover Image
Impact of hospital decision-making on drug markets : the case of biosimilars
Kanazawa, Kyogo - 2024
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015051304
Saved in:
Cover Image
The Shifting Fortunes of Corporate Psychedelia
Hager, Sandy Brian - In: Finance and Society (2025), pp. 1-23
This article traces the shifting fortunes of for-profit psychedelic medicine through two phases: a boom from 2016 to late 2021, followed by a bust that continued through late 2024. It argues that the forces driving this cycle are best understood through the concept of capitalization, which links...
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015450604
Saved in:
Cover Image
Information technology, improved access, and use of prescription drugs
Böckerman, Petri; Kortelainen, Mika; Laine, Liisa T.; … - In: Journal of the European Economic Association : JEEA 23 (2025) 1, pp. 396-430
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015357201
Saved in:
Cover Image
Greening the pharmaceutical supply chain
Belal, Md Mostain; Shukla, Vinaya; Sreejith Balasubramanian - In: Business strategy and the environment 34 (2025) 2, pp. 1917-1948
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015357789
Saved in:
Cover Image
The effect of compulsory schooling on vaccination against COVID
Monsees, Daniel; Schmitz, Hendrik - In: Health economics 34 (2025) 4, pp. 643-654
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015358537
Saved in:
Cover Image
Matters arising : cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing-remitting multiple sclerosis : a systematic review
Lazzaro, Carlo; Bergamaschi, Roberto; Zaffaroni, Mauro; … - In: Health economics review 15 (2025) 1, pp. 1-3
Background In their interesting systematic review, Gallehzan et al. quoted our article Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing-remitting multiple sclerosis (RRMS) in Italy. While we are grateful to Gallehzan et al. for their interest in the...
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015371820
Saved in:
Cover Image
The pharmacist will see you now : pharmacist prescriptive authority and access to care
Shakya, Shishir; Plemmons, Alicia; Bae, Kihwan; … - In: Contemporary economic policy : a journal of Western … 43 (2025) 1, pp. 161-174
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015373921
Saved in:
Cover Image
Evaluating quality reward and other interventions to mitigate US drug shortages
Naumov, Sergey; Noh, In Joon; Zhao, Hui - In: Journal of operations management 71 (2025) 3, pp. 335-372
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015376804
Saved in:
Cover Image
Supply base attributes and diversion risk in a supply chain for hazardous pharmaceutical products
Skilton, Paul F.; Mackelprang, Alan; Sepehrirad, Ramin; … - In: Journal of operations management 71 (2025) 3, pp. 373-392
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015376815
Saved in:
Cover Image
Towards the integration of precision medicine in psychiatric care delivery : evaluating the impact of clinical guidelines on drug-related adverse events
Yang, Jingwen; Mishra, Anant; Sinha, Kingshuk K. - In: Journal of operations management 71 (2025) 3, pp. 393-414
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015376820
Saved in:
Cover Image
A systematic review of simulation models in medicine supply chain management : current state and emerging trends.
Nabayiga, Hellen; Meer, Robert van der; Agha, Mouhamad … - 2025
Simulation modelling has widely been applied in healthcare supply chain management, focusing on blood and vaccine supply chains with less attention on the medicine supply chains. This study presents a systematic review of studies applying simulation methods, namely agent-based modelling,...
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015420227
Saved in:
Cover Image
Going through the roof : on prices for drugs sold through insurance
Kamphorst, Jurjen; Karamychev, Vladimir A. - In: Games and economic behavior 151 (2025), pp. 218-242
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015426723
Saved in:
Cover Image
Orphan medicines in the EU
European Medicines Agency - 2025
Finding effective treatment for patients with rare diseases can be very difficult. Since the EU orphan regulations entered into force in 2000, it has played a central role in facilitating the development and authorisation of medicines for rare diseases.
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015428269
Saved in:
Cover Image
Human medicines in 2024
European Medicines Agency - 2025
In 2024, EMA recommended 114 medicines for marketing authorisation. Of these, 46 had a new active substance which had never been authorised in the European Union (EU) before. Among these are a number of medicines that stand out due to their contribution to address public health needs or the...
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015428282
Saved in:
Cover Image
Veterinary medicines in 2024
European Medicines Agency - 2025
EMA has published an overview of its key recommendations of 2024 regarding the authorisation and safety monitoring of veterinary medicines. In 2024, EMA recommended 25 veterinary medicines for marketing authorisation - the highest ever number of recommendations in a year. Of these, two had a new...
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015428283
Saved in:
Cover Image
Human medicines in 2024
European Medicines Agency - 2025
In 2024, EMA recommended 114 medicines for marketing authorisation. Of these, 46 had a new active substance which had never been authorised in the European Union (EU) before. Among these are a number of medicines that stand out due to their contribution to address public health needs or the...
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015428315
Saved in:
Cover Image
Veterinary medicines in 2024
European Medicines Agency - 2025
EMA has published an overview of its key recommendations of 2024 regarding the authorisation and safety monitoring of veterinary medicines. In 2024, EMA recommended 25 veterinary medicines for marketing authorisation - the highest ever number of recommendations in a year. Of these, two had a new...
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015428406
Saved in:
Cover Image
Seizing opportunities in a changing medicines landscape : the European medicines agencies network strategy 2028
European Medicines Agency - 2025
In the last quarter of 2020, the European medicines agencies network - comprising national competent authorities (NCAs) and the European Medicines Agency (EMA) - published its five-year strategy covering the period from 2021 to 2025. The strategy (EMANS 2025) has now undergone an update to cover...
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015428829
Saved in:
Cover Image
Seizing opportunities in a changing medicines landscape : the European medicines agencies network strategy 2028
European Medicines Agency - 2025
In the last quarter of 2020, the European medicines agencies network - comprising national competent authorities (NCAs) and the European Medicines Agency (EMA) - published its five-year strategy covering the period from 2021 to 2025. The strategy (EMANS 2025) has now undergone an update to cover...
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015428951
Saved in:
Cover Image
EU drug market : MDMA : in-depth analysis
European Monitoring Centre for Drugs and Drug Addiction - 2025
EU Drug Market: MDMA describes the European MDMA market from production to trafficking, distribution and use. It details the materials, processes and players involved at different stages and levels of the market. The module takes a threat assessment approach, identifying key issues and defining...
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015429112
Saved in:
Cover Image
Critical medicines act : improving the availability and securing supply of critical medicines in the EU
European Commission / Directorate-General for Health … - 2025
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015429148
Saved in:
Cover Image
Protocol for COVID-19 vaccine effectiveness multi-country study (VEBIS) using health data registries : version 3.0
Monge Corella, Susana (contributor);  … - European Centre for Disease Prevention and Control - 2025
This protocol presents an updated common methodology for estimating COVID-19 vaccine effectiveness (VE) using established health data registries in participating European Union (EU) and European Economic Area (EEA) Member States. This work is performed within the Vaccine Effectiveness, Burden...
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015429185
Saved in:
Cover Image
Global inequality in vaccine access, mortality and economy : an agent-based exploration
Mellacher, Patrick; Plakolb, Simon - 2025
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015437546
Saved in:
Cover Image
The hard pursuit of optimal vaccination compliance in heterogeneous populations
Rampa, Giorgio; Saraceno, Margherita - In: Review of law and economics : publ. in cooperation with … 21 (2025) 1, pp. 91-119
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015437564
Saved in:
Cover Image
Injection practices as seen by drug users in Senegal. an analysis of a "magnifying glass" effect of global health
Ndione, Albert Gautier; Desclaux, Alice; Ba, Idrissa; … - In: Journal of illicit economies and development : JIED 7 (2025) 1, pp. 40-53
Sharing used injection equipment is one of the main ways in which drug users run the risk of infection (e.g., with HIV, or hepatitis B and C). This has led to the introduction of harm reduction (HR) strategies, such as needle exchange programmes (NEPs). Injection use is considered to be less...
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015437922
Saved in:
Cover Image
Modelling the global economic impact of antimicrobial resistance in humans
Countryman, Amanda M.; McDonnell, Anthony - 2025
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015405411
Saved in:
Cover Image
Firm-level innovation and the role of political capabilities : evidence for the pharmaceuticals industry
Saha, Amrita; Pozo Segura, Juan Manuel del; Palazzo, Gabriel - 2025
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015405762
Saved in:
Cover Image
Deciphering the risk-return dynamics of pharmaceutical companies using the GARCH-M model
Kaur, Arvinder; Chavali, Kavita - In: Risks : open access journal 13 (2025) 5, pp. 1-24
This study focuses on the precise forecasting of stock price movement to determine returns, diversify risk, and demystify existing opportunities. It also aims to gauge the difference in terms of the stock volatility of various pharma companies before and during the pandemic era. The prediction...
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015409027
Saved in:
Cover Image
Parental separation and its impact on childhood vaccination : evidence from Italy
Guetto, Raffaele; Tocchioni, Valentina; Dorgali, Maria … - 2025
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015413302
Saved in:
Cover Image
Advances in health: implications and challenges of intellectual property in the era of precision medicine
Veiga, Cássia Rita Pereira da; Veiga, Claudimar Pereira da - In: Journal of open innovation : technology, market, and … 11 (2025) 2, pp. 1-16
This study explores the role of intellectual property (IP) in developing and commercializing melanoma biomarkers within the pharmaceutical market, focusing on precision medicine (PM). It investigates five key areas: (i) inventiveness dynamics, (ii) commercial and epidemiological motivations for...
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015413918
Saved in:
Cover Image
Opportunity unlocked : how UK medicine spend policy can free the life sciences sector to drive growth
WPI Economics Limited - 2025
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015414036
Saved in:
Cover Image
Annual report 2024 : the European Medicines Agency's contribution to science, medicines and health in 2024
European Medicines Agency - 2025
Welcome to the 2024 EMA annual report, which highlights milestones and achievements of the past year, and our regulatory network's commitment to bringing value to public and animal health in the European Union (EU).
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015452756
Saved in:
Cover Image
Health and social responses : distribution of harm reduction equipment for high-risk drug use
European Monitoring Centre for Drugs and Drug Addiction - 2025
This page provides an overview of key issues related to the provision of harm reduction equipment for high-risk drug use, including service delivery, guidance and evidence, and considerations for implementation. It also considers implications for policy and practice.
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015452928
Saved in:
Cover Image
mRNA technology transfer hub and intellectual property : towards a more equitable and sustainable model
Adekola, Tolulope Anthony; Mercurio, Bryan - In: World trade review 24 (2025) 2, pp. 302-320
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015453680
Saved in:
Cover Image
Are veterinary drug maximum residue limits protectionist? : international evidence
Okunola, Akinbode; Dennis, Elliott; Beghin, John C. - In: Applied economic perspectives and policy 47 (2025) 3, pp. 1209-1231
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015454671
Saved in:
Cover Image
Can the size and duration of clinical trials in new drug applications predict post-approval safety warnings?
Clark, Jeremy; Menclova, Andrea Kutinova - 2025
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015394355
Saved in:
Cover Image
Technological autonomy or global integration : navigating vaccine dependency in LMICs
Marin, Anabel; Morales, Jose - 2025
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015394620
Saved in:
Cover Image
Cost effectiveness of a GP delivered medication review to reduce polypharmacy and potentially inappropriate prescribing in older patients with multimorbidity in Irish primary care : the SPPiRE cluster randomised controlled trial
Gillespie, Paddy; Moriarty, Frank; Smith, Susan M.; … - In: The European journal of health economics 26 (2025) 3, pp. 427-454
Background Evidence on the cost effectiveness of deprescribing in multimorbidity is limited. Objective To investigate the cost effectiveness of a general practitioner (GP) delivered, individualised medication review to reduce polypharmacy and potentially inappropriate prescribing in older...
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015394752
Saved in:
Cover Image
Trends in NICE technology appraisals of non-small cell lung cancer drugs over the last decade
Westerink, Lotte; Wolters, Sharon; Zhou, Guiling; … - In: The European journal of health economics 26 (2025) 3, pp. 455-471
Objectives The aim of this study is to analyse the trends in technology appraisals for non-small cell lung cancer (NSCLC) treatments performed by the National Institute for Health and Care Excellence (NICE) over the last ten years. Methods A systematic search was conducted for single technology...
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015394753
Saved in:
Cover Image
An assessment of the implications of distribution remuneration and taxation policies on the final prices of prescription medicines : evidence from 35 countries
Leon, Giovanny; Carbonel, Christophe; Rampuria, Aparajit; … - In: The European journal of health economics 26 (2025) 3, pp. 513-536
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015394765
Saved in:
Cover Image
What economists should know about the 340B Drug Discounting Program
Courtemanche, Charles; Garuccio, Joseph - 2025
The 340B Drug Pricing Program was instituted to bolster the health care safety net without relying on taxpayer money. It allows participating health care facilities - most of which are hospitals - to purchase drugs filled at in-house or contracted external pharmacies at discounts from...
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015395374
Saved in:
Cover Image
The EU community pharmacy market : the density and its influencing factors
Schwaabe, Selina - 2025
Community pharmacies deliver high-quality health care and are responsible for medication safety. The goal of the government is to ensure nationwide, accessible, and affordable medical health-care services provided by pharmacies. Therefore, the per capita density of community pharmacies matters....
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015211718
Saved in:
Cover Image
Combating vaccine hesitancy : the case of HPV vaccination
Díaz, Lina; Martínez, Déborah; Márquez, Karina; … - 2025
Cervical cancer, primarily caused by persistent Human Papillomavirus (HPV) infection, remains one of the leading causes of cancer-related deaths among women in developing countries. Although HPV vaccines are widely available in these regions, vaccine uptake remains persistently low. To address...
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015271625
Saved in:
Cover Image
Privacy regulation and R&D investments : causal evidence from global pharmaceutical and biotechnology firms
Heli, Koski - 2025
This paper examines the effects of data privacy regulation on R&D investment in the pharmaceutical and biotechnology sectors. In these industries, access to personal health data is essential for innovation, particularly in clinical research. Leveraging a firm-level panel of the world's top R&D...
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015447150
Saved in:
Cover Image
Drug pricing models, no "one-size-fits-all" approach : a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape
Manders, Evert A.; Berg, Sibren van den; Visser, Saco J. de - In: The European journal of health economics 26 (2025) 4, pp. 683-696
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015448455
Saved in:
Cover Image
The effect of workload on primary care doctors on referral rates and prescription patterns : evidence from English NHS
Pilvar, Hanifa; Watt, Toby - In: The European journal of health economics 26 (2025) 5, pp. 817-837
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015448576
Saved in:
Cover Image
Resilient COVID-19 vaccine supply chain : an optimization and simulation approach for multi-objective management
Khalilpoor, Saeedeh; Kamran, Mehdi A.; Solimanpur, Maghsud - In: Transportation research : an international journal 201 (2025), pp. 1-38
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015451707
Saved in:
Cover Image
The threat of pharmaceutical crime in the EU and beyond
European Union Agency for Law Enforcement Cooperation - 2025
This report outlines the threat of pharmaceutical crime in the EU and beyond, as assessed by Europol. It aims to raise awareness of the ways criminal networks exploit consumers and industry in generating illegal revenue through producing and selling counterfeit medicines.
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015322789
Saved in:
Cover Image
Why are opioid prescribing rates higher in rural versus urban areas?
Sasser, Alicia; Young, Gary J.; Hasan, Md Mahmudul; … - 2025
Patients in rural areas have higher rates of opioid use and overdose than those in urban areas that are linked to the greater prevalence and amounts of opioids prescribed. We merge individual claims data with county-level supply and demand factors to examine this relationship between...
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015324281
Saved in:
Cover Image
Optimal co-development contracts for companion diagnostics
Batun, Sakine; Begen, Mehmet A.; Zaric, Gregory S. - In: European journal of operational research : EJOR 323 (2025) 1, pp. 241-252
Persistent link: https://www.econbiz.de, ebvufind01.dmz1.zbw.eu/10015415589
Saved in:
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next
  • Last
A service of the
zbw
  • Sitemap
  • Plain language
  • Accessibility
  • Contact us
  • Imprint
  • Privacy

Loading...